Feng Chi Biotech (ROCO:6744) Other Stockholders Equity: NT$23.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6744 Feng Chi Biotech Corp ROCO:6744
82 GF Score
Price NT$15.80
GF Value NT$20.81
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Feng Chi Biotech Other Stockholders Equity?

Feng Chi Biotech ROCO:6744 82 Other Stockholders Equity is NT$23.6 Mil as of Dec. 2025. GuruFocus rates ROCO:6744 with a GF Score™ of 82/100 and a GF Value™ of NT$20.81 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Feng Chi Biotech's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$23.6 Mil.

Feng Chi Biotech's quarterly Other Stockholders Equity increased from Dec. 2024 (NT$21.8 Mil) to Jun. 2025 (NT$22.6 Mil) and increased from Jun. 2025 (NT$22.6 Mil) to Dec. 2025 (NT$23.6 Mil).

Feng Chi Biotech's annual Other Stockholders Equity increased from Dec. 2023 (NT$18.0 Mil) to Dec. 2024 (NT$21.8 Mil) and increased from Dec. 2024 (NT$21.8 Mil) to Dec. 2025 (NT$23.6 Mil).

Feng Chi Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Feng Chi Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech Other Stockholders Equity Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.15 15.46 18.05 21.78 23.62

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.05 20.33 21.78 22.64 23.62
ROCO:6744
82GF Score
Feng Chi Biotech Corp ROCO:6744
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Feng Chi Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$23.6 Mil mean?
Feng Chi Biotech (ROCO:6744) has a Other Stockholders Equity of NT$23.6 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Feng Chi Biotech and its competitors.
Is Feng Chi Biotech's Other Stockholders Equity too high?
Feng Chi Biotech's current Other Stockholders Equity is NT$23.6 Mil. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's Other Stockholders Equity compare to VRTX and REGN?
Feng Chi Biotech's Other Stockholders Equity of NT$23.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Feng Chi Biotech and its competitors. Feng Chi Biotech's current Other Stockholders Equity is NT$23.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.81, compared to a current price of NT$15.80 — trading 24.1% below its estimated fair value. The current Other Stockholders Equity is NT$23.6 Mil. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current Other Stockholders Equity is NT$23.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?

Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued. The current stock price of NT$15.80 is trading 24.1% below its estimated GF Value™ of NT$20.81. GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.

Key valuation signals for ROCO:6744:

  • Other Stockholders Equity: NT$23.6 Mil
  • GF Value™: NT$20.81 vs. price of NT$15.80 (24.1% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Feng Chi Biotech Business Description

Address No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score

Get the complete analysis for ROCO:6744

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.80
Price
NT$20.81
GF Value